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Abstract
There is evidence that MRSA ST398 of animal origin is only capable of temporarily occupying the human nose, and it is
therefore, often considered a poor human colonizer. We inoculated 16 healthy human volunteers with a mixture of the
human MSSA strain 1036 (ST931, CC8) and the bovine MSSA strain 5062 (ST398, CC398), 7 weeks after a treatment with
mupirocin and chlorhexidine-containing soap. Bacterial survival was studied by follow-up cultures over 21 days. The human
strain 1036 was eliminated faster (median 14 days; range 2–21 days) than the bovine strain 5062 (median 21 days; range 7–
21 days) but this difference was not significant (p= 0.065). The bacterial loads were significantly higher for the bovine strain
on day 7 and day 21. 4/14 volunteers (28.6%) showed elimination of both strains within 21 days. Of the 10 remaining
volunteers, 5 showed no differences in bacterial counts between both strains, and in the other 5 the ST398 strain far
outnumbered the human S. aureus strain. Within the 21 days of follow-up, neither human strain 1036 nor bovine strain 5062
appeared to acquire or lose any mobile genetic elements. In conclusion, S. aureus ST398 strain 5062 is capable of adequately
competing for a niche with a human strain and survives in the human nose for at least 21 days.
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Introduction
Staphylococcus aureus (S. aureus) is a well known pathogen and is
capable of colonizing the skin and mucosa of humans with the
anterior nares being the most common carriage site [1]. Three
human nasal carriage patterns can be distinguished: the persistent
(30%), intermittent (40%) and non-carriage (30%) pattern [2].
This was recently reduced to two major phenotypes: persistent and
non-carriage only [3]. Importantly, nasal carriage of S. aureus
increases the risk for infection with this bacterial species [4]. The
control of methicillin-resistant S. aureus (MRSA) reservoirs and
infections is often problematic because these populations are
resistant to almost al b-lactam antibiotics, the treatment of choice
for Staphylococcal infections, and are often resistant to other
commonly prescribed antibiotics [5]. Recently there has been a
worldwide change in the epidemiology of MRSA. MRSA
populations have been a problem in hospitals worldwide since
the 1960s, but the emergence of new clones of MRSA has
occurred in the community among individuals who lacked contact
with healthcare [6]. In the US nearly all MRSA are associated
with the community-associated (CA)-MRSA USA300 clone [7].
Nowadays in many European countries, Northern Americas,
Australia and Asia there has also been an increased incidence of
carriage of a livestock-associated (LA)-MRSA, especially in people
with direct contact with livestock, such as farmers and veterinar-
ians [8]. The majority of these LA-MRSA cases are caused by
MRSA multi-locus sequence type (ST) 398, a lineage that can be
detected by the fact that strains are Pulsed Field Gel Electropho-
resis (PFGE) non-typeable, by restriction-modification (RM)
testing and PCR testing [9,10].
Currently ST398 MRSA/MSSA is reported in hospitals where
it caused a broad spectrum of relatively mild infections including
soft skin and tissue infections (SSTI) [11,12], abscesses, urinary
tract infections (UTI) and wound infections [13,14]. In rare cases
severe infections such as endocarditis [15] and bacteraemia [13]
have been observed, although these occurred in older patients with
underlying diseases. Often these cases were livestock-associated
but occasionally infections occurred in people lacking contact with
livestock.
The level of intensity and the duration of direct contact with
livestock are important factors in proving positive for MRSA
ST398. Prevalence of MRSA ST398 in farm-workers decreases
substantially during holidays and in periods of less intense contact
with livestock [16]. Van Cleef et al. showed that humans, who are
temporarily in close contact with livestock, easily acquire MRSA
ST398 but also shed the strain in less than 24 hours [17]. Whilst,
in the hospital environment, Wassenberg et al. showed that
nosocomial transmission of ST398 is 72% less likely to occur
compared to non-ST398 strains [18]. It remains unclear whether
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these low rates of transmission and persistence are pathogen or
patient-related.
S. aureus adapt to different host environments by acquiring
mobile gene elements (MGEs) carrying genes encoding host-
specific immune evasion strategies. The best characterised human-
specific factor is the Q3 bacteriophage that carries the immune
evasion cluster (IEC) genes chp, sak and scn [19]. This bacterio-
phage is commonly found in human S. aureus but is rare amongst
animal S. aureus [20,21]. Recently it was shown that many ST398
isolates of human origin do not carry the Q3 bacteriophage or any
of the IEC genes suggesting that ST398 can survive and even
cause infection in the human host without acquisition of the Q3
bacteriophage [22].
At the moment data concerning the intrinsic capacity of ST398
to colonize the human nose are lacking. In this study, we
undertook an artificial human inoculation experiment with a
mixed inoculum of a bovine MSSA ST398 (CC398) strain and
human MSSA ST931 (CC8) strain, 7 weeks after a treatment with
mupirocin and chlorhexidine-containing soap, and determined
their ability to survive in the anterior nares. In addition, we used
microarray analysis to compare the genomes of parental strains
and strains that survived in the nose.
Materials and Methods
Study population
Twenty-two healthy volunteers were included in this study
(seven males and fifteen females, median age of 27 years, range
19–57 years). An infectious disease physician was on call for the
entire study period and all volunteers provided their written
informed consent. The study protocol was approved by the local
Medical Ethical Committee of the Erasmus University Medical
Centre Rotterdam, The Netherlands (MEC-2011-131).
S. aureus strains
The human S. aureus strains (502A, 274, 1036, P1, P2 and I)
were all used in earlier inoculation experiments [3,23]. The bovine
MSSA ST398 strains used in this study were obtained in 2008
from healthy calves in The Netherlands as part of a MRSA
prevalence study [24]. Of the MSSA ST398 strains we also
obtained MRSA counterparts, which were isolated from the same
calf. For determination of the genetic background MLST analyses
[25] and spa-typing were performed [26]. The agr locus was
amplified to determine the agr-type (1–4) [27]. The detection of sea
– seu, tst [28], eta, etb and lukS/lukF [29] was performed by PCR.
PCR analysis with ST398-specific primer set A07 [10] was
performed. The VITEK (bioMe´rieux, Marcy l’Etoile, France) was
used to determine the antibiotic susceptibility of the strains. For a
second opinion, the strains were sent to the National Institute for
Public Health and the Environment (RIVM, Bilthoven, The
Netherlands), and were analyzed for toxin production. Bacterial
growth rates of the strains were determined in Brain Heart
Infusion (BHI) and Tryptic Soy Broth (TSB). Bacteria were grown
for 7 hours at 37uC.
Artificial inoculation protocol
The artificial inoculation protocol was as described previously
[3,20,30]. In brief, before inoculation the carriage state for S. aureus
was determined by taking two nasal swabs with an interval of one
week. We defined carriers as persons with two consecutive nasal
swabs culture-positive for S. aureus. A non-carrier had one or no
positive nasal cultures. Blood was drawn in week 1 to determine C-
reactive protein (CRP) levels (mg/L) and the leukocyte number
(*10E9/L). After determining their carriage state, all volunteers
were instructed to use mupirocin nasal ointment (2%; Glaxo-
SmithKline, Waltham, MA, USA) twice daily and chlorhexidine-
containing soap once daily for five days as eradication treatment
for S. aureus. The volunteers received hygienic advice and medical
check-ups. These medical check-ups included questions about
signs of infection and when indicated physical examination.
Volunteers remaining positive for S. aureus after eradication
treatment were excluded from the inoculation phase. Therefore,
the anterior nares were again cultured six weeks after the
treatment to determine if the treatment had been successful.
Artificial inoculation was performed in successfully decolonized
volunteers one week later by applying 10*7 CFU per strain in the
left and right nostril using a 1:1 mixture of human strain 1036 and
bovine strain 5062. In the follow-up period the anterior nares were
cultured on day 1, 2, 4, 7, 10, 14 and 21 after inoculation. At the
end of the study, pharyngeal and perineal swabs were cultured as
well. CRP and the leukocyte number were again determined on
day 21. Eradication treatment was given to volunteers still carrying
the inoculated S. aureus strain(s) at the end of follow-up.
Nasal swab cultures
The nose was sampled by revolving a single swab around both
the left and right anterior nares four times. Swabs were submerged
in Stuart’s transport medium and vortexed (15 s). Swab eluates
were cultured quantitatively at 37uC via plating of serial dilutions
of the eluates on phenol red mannitol salt agar plates (PHMA) (2
days). The eluted swabs were submerged and incubated in phenol
red mannitol salt broth (PHMB) for 7 days at 37uC. The PHMA
culture plates were incubated at room temperature for 5 further
days. Both strain 1036 and 5062 are morphologically distinguish-
able by colony colour which was used to determine the total
density of each strain per swab. Furthermore, strain 5062 ferments
lactose while strain 1036 does not. Therefore, twenty-five colonies
of each morphotype were selected by colour and placed on lactose
agar plates for verification. A latex agglutination test (Slidex Staph
Plus, bioMe´rieux, Marcy-l’Etoile, France) was performed for
suspected colonies (yellow colour and/or haemolytic zone). For
final identification, ten out of the twenty-five isolates of each
morphotype were analyzed by PCR-analysis of the spa-gene.
Microarray analysis
Microarray experiments were performed using a 62-strain S.
aureus microarray (SAM-62), as previously described (McCarthy et
al. 2011). SAM-62 contains 29,739 60-mer oligo probes repre-
senting 6,520 genes, and an additional 579 gene variants, from the
first 62 sequenced S. aureus genomes and from 153 sequenced
plasmid genomes. The array design is available in BmG@Sbase
(Accesion No. A-BUGS-38; http://bugs.sgul.ac.uk/A-BUGS-38)
and ArrayExpress (Accession No. A-BUGS-38). All data analysis
was performed in GeneSpring GX v11.01 (Agilent Technologies).
Fully annotated microarray data have been deposited in
BmG@Sbase (accession number E-BUGS-131; http://bugs.sgul.
ac.uk/E-BUGS-131) and also ArrayExpress (accession number E-
BUGS-131).
Statistical analysis
Statistical analyses were performed with SPSS, version 17.0
(SPSS Inc., Chicago, IL, USA). The primary outcome after
artificial inoculation was the survival time of S. aureus in the nose.
We defined survival time as the time in days until the final positive
nasal culture for each of the inoculated S. aureus strains. A Kaplan-
Meier survival analysis (log-rank test) was used to compare survival
between the human and bovine strain. The Mann-Whitney U-test
Human Nasal Survival of S. aureus ST398
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All S. aureus strains were extensively analysed for genetic
background, toxin gene content, agr-type and antibiotic resistance
profile. For obvious ethical reasons, MSSA deficient in toxin
genes, sensitive to as many antibiotics possible, sharing the same
agr-type and growth characteristics were selected for the inocula-
tion experiment. Therefore, out of the initially 6 human isolates,
we selected strain 1036 which belonged to ST931 (CC8). The
strain was susceptible to all common antimicrobials (e.g. mupir-
ocin, flucloxacillin and vancomycin), had agr-type 1 and lacked
superantigens (sea – seu, tst), enterotoxins (eta, etb) and lukS/lukF.
The selected bovine strain was 5062 and belonged to ST398
(CC398). This strain was resistant to tetracycline and trimetho-
prim, but was susceptible to other common antimicrobials and was
devoid of the staphylococcal toxins mentioned above. This strain
had agr-type 1 and spa-type t034. PCR analysis with primer set
A07 confirmed that strain 5062 was of the ST398 lineage. The
MRSA ST398 counterpart that was isolated from the same calf
shared the same spa-type, PFGE-type and other characteristics
(e.g. gene content, antibiotic susceptibility) except for the presence
of the mecA-gene. The RIVM confirmed that both the human and
bovine strain was not producing the staphylococcal toxins
mentioned above. Growth kinetics in Brain-Heart Infusion (BHI)
were comparable for strain 1036 and 5062 (data not shown).
Artificial nasal inoculation with human strain 1036 and
bovine strain 5062
A total of 22 volunteers were included in the study and their
carriage state was determined. Six volunteers (27%) were classified
as carriers and sixteen volunteers (73%) were classified as
noncarriers. All volunteers used the eradication treatment as
described and six weeks after the treatment five carriers were
positive for S. aureus and they were therefore excluded from further
intervention and follow-up. One participant was excluded because
of private reasons. The remaining sixteen volunteers (1 carrier; 15
non-carriers) were inoculated with a mixture of the two strains
seven weeks after the treatment. Two volunteers were excluded
from further analyses because of the use of antibiotics during the
study period. One started antibiotics for UTI on the day of
inoculation; the other participant developed an intranasal furuncle
which was treated. All volunteers adhered to the study protocol.
S. aureus survival was determined by quantitative cultures of 7
consecutive nasal swabs (day 1, 2, 4, 7, 10, 14, 21) in a period of 21
days. The Kaplan-Meier curves in Figure 1 show the proportion of
positive cultures during follow-up. Overall the human strain 1036
was eliminated at a faster pace (median 14 days; range 2–21 days)
than the bovine strain 5062 (median 21 days; range 7–21 days) but
this difference was not significant (p=0.065).
The densities of the two strains in the anterior nares rapidly
decreased during the first days after inoculation. When the
differences in bacterial counts between the human and bovine
strain were studied on day 7 and 21, significantly higher densities
were found for the bovine strain in comparison to the human
strain (respectively p=0.012 and p=0.015) (Fig. 2).
Two patterns of elimination of the inoculated strains were
observed. One group of volunteers (28.6%, n=4/14; 4 non-
carriers) showed elimination of both strains within 21 days
(Fig. 3A), while in the remaining 10 volunteers (71.4%; 1 carrier,
9 non-carriers) S. aureus was culture-positive up to day 21 until the
end of the study. Interestingly, this last group of 10 volunteers
could be further sub-divided. In 5 volunteers (1 carrier, 4 non-
carriers) no differences in bacterial counts between both strains
were observed during the 21 days (Fig. 3B). In contrast, in the
remaining 5 volunteers (all non-carriers) strain 5062 far outnum-
bered strain 1036 (Fig. 3C).
An increase in bacterial load of the bovine strain at the end of
the follow-up period could indicate adaptation to the host or
waning of the host immune response. In order to study if
acquisition of MGEs by (one of) the inoculated strains could have
occurred, microarray analysis was performed on both parent
strains as well as on every last positive culture isolate for strain
1036 and 5062 from the 10 volunteers who showed no elimination
of both strains within 21 days. The parent human strain 1036
carried a S. aureus pathogenicity island (SaPI)2, plasmids with rep
genes rep5, rep21, rep23 and rep30, and genes cadDX and qacA
conferring resistance to cadmium and antiseptics (Figure S1). This
Figure 1. Survival of the inoculated strains. Kaplan-Meier survival
curves showing the proportion of volunteers who are S. aureus culture-
positive after the artificial inoculation with human strain 1036 and
bovine strain 5062.
doi:10.1371/journal.pone.0048896.g001
Figure 2. Bacterial loads in the nares of volunteers after
inoculation. Each dot represents the number of CFUs per swab at day
1, 2, 4, 7, 10, 14 and 21 after the inoculation with the mixture of S.
aureus strain 1036 of human origin and strain 5062 of bovine origin. The
horizontal bars represent the median number of CFUs at indicated
sampling times.
doi:10.1371/journal.pone.0048896.g002
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strain did not carry the Q3 bacteriophage or any of the IEC genes.
The parent bovine strain 5062 carried the Q6 bacteriophage and
the tetM and dfrG genes encoding resistance to tetracycline and
trimethoprim.
After 21 days of follow-up, the bovine 5062 strains did not
acquire any MGE from the human strains in any of the 10
volunteers. In addition, no bovine strain lost an MGE that was
present in the parental strain, although microheterogeneity was
detected in some of these bovine strains. Likewise, the human
1036 strains did not acquire or lose any MGEs. In these human
strains microheterogeneity was also seen, but this was not due to
acquisition of MGEs. We note that isolate H1036 from volunteer
23 has the Q6 integrase gene, but as it does not possess any other
bacteriophage genes we are confident this is a false positive.
At the end of the study, all volunteers were in healthy condition.
Laboratory values indicated no signs of infection. In five
volunteers, all nasal swabs and two pharyngeal swabs were still
positive for the inoculated bovine strain 5062. In five other
volunteers, all nasal swabs and four pharyngeal swabs were
positive for both of the inoculated strains. Eradication treatment
was given to all these volunteers. Nasal and pharyngeal swabs
following eradication treatment were all negative.
Discussion
We demonstrate in an artificial human nasal inoculation model,
that S. aureus ST398 of bovine origin is capable of surviving in the
nose in 10 healthy volunteers for at least 21 days when inoculated
7 weeks after an eradication treatment with mupirocin and
chlorhexidine-containing soap. We found no evidence that
survival of ST398 in the human host was due to the acquisition
of MGEs. There is evidence that MRSA ST398 of animal origin is
only capable of temporarily occupying the human nose. It is,
therefore, often considered as a poor human colonizer [17,31].
Our study shows this loss of colonization in livestock workers is not
due to an intrinsic inability of ST398 to survive in the human nose.
Van Cleef et al. showed that MRSA ST398 can easily be
acquired but is also lost within 24 hours by those who are
temporarily in close contact with livestock [17]. An explanation for
the discrepancy between our data and that of van Cleef et al. could
be the inoculum size and or immunological effect. In our
inoculation experiment we used an inoculum of 10*7 bacteria
per strain per nostril, but currently it is not known what the level of
bacterial exposure is during an average day of farming. It could
very well be that this is a much lower number of bacteria than the
inoculum we used. Another difference between our study and
exposure to ST398 on farms is that we pretreated all our
volunteers with mupirocin, an intervention that may eradicate
other elements of the nasal microflora, coagulase-negative
staphylococci in particular, that play a role in the resistance of
the nose against S. aureus colonization [32].
In the first days after inoculation we observed a rapid decrease
in bacterial load of both strains in the nares of all volunteers,
resulting in the elimination of both strains within 21 days in four
volunteers. Interestingly, in the remaining 10 volunteers ST398
could still be detected after 21 days. In half of this latter group we
observed, after a decrease in bacterial loads of both strains, that
the loads stabilized after 21 days. In the remaining five individuals,
cell counts for strain ST398 increased at the end of follow-up
where in most of these cases the human strain was eliminated. Our
data clearly indicate that in 28.6% of the volunteers S. aureus is
rapidly eradicated even when exposed to significant numbers of
bacteria. Yet, 71.4% of the volunteers were not able to eradicate
either or one of the inoculated S. aureus strains.
We found no evidence that persistence of ST398 in the human
host was due to the acquisition of MGEs. This suggests that animal
ST398 is able to survive for several weeks in the human nares
without gaining or losing MGEs. This agrees with a previous study
that showed that human-specific Q3 bacteriophage and the IEC
genes encoding chp, sak and scn are absent in the majority of ST398
isolates from humans [22]. How does ST398 colonize different
host species? S. aureus encode multiple surface proteins that interact
with host ligands, and many of these proteins often have
overlapping functions and can function in multiple hosts [33].
In conclusion, MSSA strain 5062 of bovine origin (ST398, spa-
type t034) is capable of surviving in the human nose for at least 21
days where it appears to successfully compete with human strain
1036.
Supporting Information
Figure S1 SAM-62 microarray analysis of parent strains
and colonizing isolates in 10 human volunteers Isolates are
represented by vertical lines and information about the origin of
each isolate is given at the top of the figure. Group 1 are the
volunteers in whom no difference in bacterial load between both
strains was observed (Fig. 3B) and Group 2 are those who did show
a difference in bacterial load between both strains at the end of
follow-up (Fig. 3C). Horizontal lines represent 57 different 60-mer
oligo probes specific to 5 hsdS variants, 4 bacteriophage genes, 1
SaPI gene, 4 plasmid rep families, and 5 different antimicrobial,
biocide and heavy metal resistance genes. The colour depicts if the
gene is present or absent in the respective isolate; red or
yellow= present, blue or black = absent. After 21 days of follow-
up, neither human strains 1036, nor bovine strains 5062 acquired
or lost any MGEs.
(TIF)
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